{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either \"unrelated\" or \"unlikely to be related\" to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.","groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"OG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"paramType":"NUMBER","populationDescription":"Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.","reportingStatus":"POSTED","timeFrame":"Up to 30 days post-treatment","title":"Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment","type":"SECONDARY","unitOfMeasure":"percentage of patients"}